Listing Patents on Balance Sheets: GAAP & IndAS

Patents represent enforceable legal monopolies, but their treatment in financial statements is governed by accounting standards rather than intellectual property law. A granted patent does not automatically qualify for recognition as an asset on the balance sheet. Whether a patent appears in financial statements depends on how it was created, acquired, and supported by evidence of future economic benefit.

For companies raising capital, undergoing audits, or preparing for mergers and acquisitions, understanding the accounting treatment of patents is essential. Misclassification or aggressive capitalization can undermine credibility during investor due diligence, while overly conservative treatment can obscure the economic strength of an innovation-driven business.

Foundational Accounting Standards for Patent Recognition

Scope of IndAS 38 and US GAAP ASC 350

In India, patents are governed by IndAS 38 (Intangible Assets), which is aligned with IFRS principles. IndAS 38 applies to identifiable non-monetary assets without physical substance, including patents, trademarks, and technical know-how, unless another standard applies.

In the United States, patent accounting falls primarily under ASC 350 (Intangibles – Goodwill and Other), read alongside ASC 730 (Research and Development). US GAAP is significantly more conservative than IndAS in its treatment of internally generated intellectual property.

While both frameworks recognize acquired patents as intangible assets, they diverge sharply when dealing with internally developed patents.

Definition of Intangible Assets in Financial Statements

To qualify for balance sheet recognition under both IndAS and GAAP, a patent must satisfy three conditions:

·         Identifiability - The patent must arise from legal or contractual rights or be capable of being separated and transferred independently.

·         Control - The company must have the ability to obtain future economic benefits from the patent and restrict others from accessing those benefits. Legal ownership under the Patents Act, 1970 is a necessary but not sufficient condition.

·         Future Economic Benefits - There must be a reasonable expectation of revenue generation, cost reduction, licensing income, or strategic commercial advantage.

Failure to satisfy any one of these conditions prevents capitalization, regardless of patent grant status.

Recognition Criteria for Internally Generated Patents

The Research Phase: Mandatory Expensing

IndAS 38 requires that all costs incurred during the research phase be expensed immediately. Research includes activities aimed at gaining new technical knowledge without demonstrable commercial feasibility.

Typical research activities include:

·         Concept formulation

·         Exploratory testing

·         Alternative evaluation

·         Early experimentation

Patent-related costs incurred during this phase cannot be capitalized under any circumstances.

The Development Phase: Six Criteria for Capitalization

Once a project enters the development phase, capitalization becomes possible, but only if all six criteria under IndAS 38 are demonstrably met:

·         Technical feasibility of completing the patent

·         Intention to complete and use or sell the asset

·         Ability to use or sell the asset

·         Probability of future economic benefits

·         Availability of adequate technical and financial resources

·         Reliable measurement of attributable expenditure

Auditors typically require contemporaneous documentation supporting each criterion.

Technical Feasibility and Patentability Thresholds

In practice, technical feasibility often aligns with:

·         Filing of a Complete Specification

·         Favourable International Search Report or IPRP in PCT filings

·         Substantive progress during prosecution at the Indian Patent Office

A patent grant is not mandatory for capitalization, but speculative or early-stage filings rarely satisfy auditor scrutiny.

Accounting Treatment of Acquired Patents

Business Combinations under IndAS 103 and ASC 805

When patents are acquired through mergers, acquisitions, or asset purchases, both IndAS 103 and ASC 805 require recognition of identifiable intangible assets at fair value, regardless of whether the target previously capitalized them.

This frequently results in patents appearing on the acquirer’s balance sheet for the first time.

Purchase Price Allocation (PPA) and Fair Value

Purchase Price Allocation assigns acquisition consideration across tangible and intangible assets using recognized valuation approaches:

·         Income approach, including relief-from-royalty

·         Market approach using comparable transactions

·         Cost approach based on replacement cost

The allocated fair value becomes the initial carrying amount of the patent.

Measurement and Valuation Models

Cost Model vs. Revaluation Model

IndAS permits two subsequent measurement models:

·         Cost Model, where patents are carried at cost less amortization and impairment

·         Revaluation Model, permitted only if fair value can be measured reliably using an active market

·         In practice, nearly all Indian companies use the cost model.

Treatment of Patent Prosecution and Maintenance Fees

·         Filing and prosecution costs directly attributable to development may be capitalized

·         Maintenance and annuity fees are generally expensed

·         Litigation costs are usually expensed unless they demonstrably create or extend enforceable rights, which is rare and subject to conservative interpretation

Amortization, Useful Life, and Impairment Testing

Estimating Economic Life vs. Legal Patent Term

Although patents have a statutory life of 20 years, amortization must reflect the economic useful life, which is often shorter due to:

·         Technological obsolescence

·         Market shifts

·         Regulatory changes

Straight-line amortization is most common unless another pattern can be substantiated.

Triggering Events for Impairment Reviews

IndAS 36 requires impairment testing when indicators arise, including:

·         Patent invalidation or adverse prosecution outcomes

·         Commercial failure of patented products

·         Emergence of superior competing technologies

·         Regulatory or legal changes affecting enforceability

Impairment losses cannot be reversed under the cost model.

Strategic Impact on Fundraising and Valuation

EBITDA Adjustments and IP Rich Balance Sheets

Capitalizing eligible development costs shifts expenses from the profit and loss account to the balance sheet, improving EBITDA. This can materially influence valuation where EBITDA multiples are used.

However, aggressive capitalization without support increases audit and diligence risk.

Due Diligence Preparedness for Investors

Investors evaluate both legal robustness and accounting discipline. Red flags include:

·         Capitalized patents with no commercial linkage

·         Absence of documented capitalization criteria

·         Mismatch between legal ownership and accounting entity

A consistent IP accounting policy strengthens credibility.

Taxation and Depreciation under the Income Tax Act, 1961

Section 32 and Block of Assets

For tax purposes, patents qualify as intangible assets under Section 32:

·         Depreciation at 25 percent on written down value

·         Included within the block of intangible assets

Tax depreciation operates independently of accounting amortization and can provide meaningful cash flow benefits.

Frequently asked questions (FAQs)

1.    Can a granted patent always be capitalized
No. Accounting recognition depends on capitalization criteria, not grant status.

2.    Can engineer salaries be capitalized
Yes, if directly attributable to development and reliably measured.

3.    Are provisional patents capitalized
Generally no, due to lack of technical feasibility evidence.

4.    Can patents held by founders appear on company balance sheets
No, unless formally assigned and controlled by the company.

5.    Does IndAS allow patent revaluation
Only if an active market exists, which is rare.

6.    Are FTO costs capitalized
No. They are risk management expenses.

7.    What happens if a patent is finally rejected
The asset must be written off or impaired.

8.    Do auditors review patent prosecution documents
Frequently, especially for development capitalization.

9.    Are trademarks treated differently
Yes. Trademarks may have indefinite useful lives.

10. Do banks consider balance sheet patents for lending
Yes, particularly when supported by audited capitalization and valuation.